Chelation therapy: Overlooked in the treatment and prevention of diabetes complications?

Future Medicinal Chemistry

Volumn 5, Issue 10, 2013, Pages 1075-1078

  Frizzell, Norma ^a   Baynes, John W ^a  

^a UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

cardiovascular disease; chelation; diabetes; glycation; reactive oxygen species

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED LIPOXIDATION END PRODUCT; AMYLOID BETA PROTEIN; CITRIC ACID; COPPER; DEFEROXAMINE; EDETIC ACID; IRON; LIPID; PROTEIN DERIVATIVE; PROTEIN OXIDATION PRODUCT; REACTIVE OXYGEN METABOLITE; SCAVENGER RECEPTOR; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ATHEROSCLEROSIS; AUTOOXIDATION; CARDIOVASCULAR DISEASE; CATALYSIS; CEREBROVASCULAR ACCIDENT; CHELATION THERAPY; DEGENERATIVE DISEASE; DIABETES MELLITUS; DISEASE PREDISPOSITION; DRUG ACTIVITY; GAS CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; TANDEM MASS SPECTROMETRY; TISSUE INJURY;

ADVANCED OXIDATION PROTEIN PRODUCTS; ANIMALS; CARDIOVASCULAR DISEASES; CATALYSIS; CHELATION THERAPY; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; EDETIC ACID; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; METALS; REACTIVE OXYGEN SPECIES;

EID: 84879644039     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.13.73     Document Type: Review

References (17)

1. Born T, Kontoghiorghe CN, Spyrou A, Kolnagou A, Kontoghiorghes GJ. EDTA chelation reappraisal following new clinical trials and regular use in millions of patients: review of preliminary findings and risk/benefit assessment. Toxicol. Mech. Methods 23(1), 11-17 (2013).
2. Lamas GA, Goertz C, Boineau R et al. Effect of disodium EDTA chelation regimen on cardiovascular events in patients with previous myocardial infarction. The TACT randomized trial. J. Am. Med. Assoc. 309(12), 1241-1250 (2013).
3. Callaway E. Chelation-therapy heart trial draws fire: critics not persuaded that metal-snaring treatment works. Nature 491(7424), 313-316 (2012).
4. Bauchner H, Fontanarosa PB, Golub RM. Evaluation of the trial to assess chelation therapy (TACT): the scientific process, peer review, and editorial scrutiny. J. Am. Med. Assoc. 309(12), 1291-1292 (2013).
5. Nagai R, Murray DB, Metz TO, Baynes JW. Chelation: a fundamental mechanism of action of AGE inhibitors, AGE breakers, and other inhibitors of diabetes complications. Diabetes 61(3), 549-559 (2012).
6. Frizzell N, Baynes JW. Chelation therapy for management of diabetic complications: a hypothesis and a proposal for clinical laboratory assessment of metal ion homeostasis in plasma. Clin. Chem. Lab. Med. doi:10.1515/cclm-2012- 0881 (2013) (Epub ahead of print).
7. Halliwell B, Gutteridge JMC. Free Radicals in Biology and Medicine (4th Ed.). Oxford University Press, Oxford, UK (2007).
8. Goh SY, Cooper ME. The role of advanced glycation end-products in progression and complications of diabetes. J. Clin. Endocrinol. Metab. 93(4), 1143-1152 (2008). (Pubitemid 351519698)
9. Qian M, Liu M, Eaton JW. Transition metals bind to glycated proteins forming redox active "glycochelates": implications for the pathogenesis of certain diabetic complications. Biochem. Biophys. Res. Commun. 250(2), 385-389 (1998). (Pubitemid 28463887)
10. Cooper GJS. Therapeutic potential of copper chelation with triethylenetetramine in managing diabetes mellitus and Alzheimer's disease. Drugs 71(10), 1281-1320 (2011).
11. Cooper GJ. Selective divalent copper chelation for the treatment of diabetes mellitus. Curr. Med. Chem. 19(17), 2828-2860 (2012).
12. Nagai R, Nagai M, Shimasaki S, Baynes JW, Fujiwara Y. Citric acid inhibits development of cataracts and ketosis in streptozotocin (Type 1) diabetic rats. Biochem. Biophys. Res. Commun. 393(1), 118-122 (2010).
13. Brewer GJ. Copper toxicity in Alzheimer's disease: cognitive loss from ingestion of inorganic copper. J. Trace Elem. Med. Biol. 26, 89-92 (2012).
14. Brewer GJ. Metals in the causation and treatment of Wilson's disease and Alzheimer's disease, and copper lowering therapy in medicine. Inorg. Chim. Acta 393, 135-141 (2012).
15. Buettner GR. Use of ascorbate as a test of catalytic metals in simple buffers. Methods Enzymol. 186, 125-127 (1990). (Pubitemid 20279948)
16. Engelen L, Stehouwer CD, Schalkwijk CG. Current therapeutic interventions in the glycation pathway: evidence from clinical studies. Diabetes Obes. Metab. doi:10.1111/dom.12058 (2012) (Epub ahead of print).
17. Miyata T, Ueda Y, Yamada Y et al. Accumulation of carbonyls accelerates the formation of pentosidine, an advanced glycation end product: carbonyl stress in uremia. J. Am. Soc. Nephrol. 9(12), 2349-2356 (1998). (Pubitemid 28543814)